SD SDGR Schrodinger, Inc. Loading... : Investor Sentiment and Bull/Bear Views

The author lists Schrödinger as a standout AI-core company using AI and simulated physics and chemistry to discover new drugs. He argues ground-up AI companies like Schrödinger provide huge improvements over legacy competitors that must pivot or fire employees. No specific catalyst, time horizon, or risk is stated.

AI can now model cells, organs, tissue, and disease biology at scale and screen molecules computationally, shifting drug discovery from expensive trial-and-error toward data-driven target selection. Rather than picking which drug company wins, Ben prefers the tools that measure, test, collect, create, and sequence biological data, citing a basket including Danaher, Thermo Fisher, Schrödinger, Illumina, Guardant Health, and Twist Bioscience.

The author argues that because molecular discovery cycles typically take 18 to 24 months, the first candidate nomination milestones or Phase 1 advances under Schrödinger's Novartis agreement could be communicated imminently, at the end of this year or during 2027. The mechanism is that collaboration milestone announcements would validate the platform and act as a stock catalyst. The stated horizon is late this year through 2027; no explicit risk is given beyond the timing dependency of the discovery cycle.